The high bleeding risk patient
Summary
Patients at high bleeding risk (HBR) comprise a growing subgroup of patients undergoing PCI. Nonetheless, such patients have historically been excluded from or under-represented in clinical trials in PCI patients. Moreover, completed and ongoing trials aiming to enrol HBR patients use heterogeneous definitions of HBR, limiting the interpretation and comparison of results. To address this issue, the Academic Research Consortium for high bleeding risk (ARC-HBR) proposed a standardised definition of HBR patients intended for use in trials of HBR patients undergoing PCI.
Using a cut-off of BARC 3-5 bleeding of ≥4% or intracranial haemorrhage of ≥1% at one year to denote major bleeding, a list of binary major and minor HBR criteria were created based on consensus and review of the available evidence. The criteria are pragmatic, objective, and comprehensive to both trialists, physicians and patients.
The definition is intended to provide consistency in defining the HBR population for clinical trials, to complement regulatory review and ultimately, clinical decision-making. The proposed ARC-HBR consensus definition represents the first pragmatic approach to a consistent definition of HBR in clinical trials evaluating safety and effectiveness of devices and drug regimens for patients undergoing PCI. It is hoped that use of the ARC-HBR...
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
- Urban P, Mehran R, Colleran R, et al. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention: A Consensus Document From the Academic Research Consortium for High Bleeding Risk. Circulation. 2019.
- Urban P, Meredith IT, Abizaid A, et al. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. The New England journal of medicine. 2015; 373(21): 2038-47.
- Ariotti S, Adamo M, Costa F, et al. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial. JACC Cardiovascular interventions. 2016; 9(5): 426-36.
- Varenne O, Cook S, Sideris G, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018; 391(10115): 41-50.
- Windecker S, Latib A, Kedhi E, et al. Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. The New England journal of medicine. 2020; 382(13): 1208-18.
- Baber U, Mehran R, Giustino G, et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. Journal of the American College of Cardiology. 2016; 67(19): 2224-34.
- Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017; 389(10073): 1025-34.
- Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. Jama. 2016; 315(16): 1735-49.
- Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011; 123(23): 2736-47.
- Krucoff MW, Mehran R, van Es GA, Boam AB, Cutlip DE. The academic research consortium governance charter. JACC Cardiovascular interventions. 2011; 4(5): 595-6.
- Urban P, Gregson J, Owen R, et al. Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. Jama. Cardiol 2021.